Table 2.
Analysis of metaphase spreads of lymphoblastoids following H2O2 treatment
| Fusions | Breaks | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cell Type | H2O2 (μM) | Chromosomes per metaphase | T/QLS | SCF | D/T | R | EAF | Total Fusions | CB | F | UT | Total Breaks | Total Aberrations | Aberrant cells (%) |
| 0 | 45.90 ± 0.68 (44-48) |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 7 | 7 | 7 | |
| 20 | 46.04 ± 0.49 (44-48) |
0 | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 10 | 11 | 13 | 10 | |
| Normal-L | 40 | 45.82 ± 0.73 (44-48) |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 8 | 11 | 11 | 9 |
| 60 | 45.89 ± 0.77 (44-48) |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 11 | 16 | 16 | 14 | |
| 80 | 45.79 ± 0.86 (44-48) |
0 | 0 | 0 | 1 | 0 | 1 | 2 | 11 | 8 | 21 | 22 | 14 | |
| 100 | 46.03 ±0.76 (44-48) |
0 | 0 | 1 | 0 | 0 | 1 | 0 | 3 | 11 | 14 | 15 | 13 | |
| 0 | 45.83 ± 0.67 (44-48) |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 9 | 19 | 19 | 14 | |
| 20 | 45.79 ± 0.64 (44-48) |
0 | 0 | 0 | 1 | 0 | 1 | 1 | 15 | 6 | 22 | 23 | 14 | |
| XPA-L | 40 | 45.69 ± 0.99 (43-48) |
0 | 1 | 2 | 0 | 1 | 4 | 2 | 13 | 13 | 28 | 32 | 22 |
| 60 | 45.65 ± 0.79 (43-48) |
3 | 0 | 1 | 1 | 0 | 5 | 2 | 12 | 14 | 28 | 33 | 22 | |
| 80 | 45.35 ± 1.46 (41-48) |
0 | 0 | 1 | 0 | 0 | 1 | 0 | 22 | 18 | 40 | 41 | 26 | |
| 100 | 45.77 ± 0.67 (44-48) |
0 | 0 | 3 | 1 | 0 | 4 | 5 | 16 | 15 | 36 | 40 | 28 | |
| 0 | 46.49 ± 0.97 (44-48) |
0 | 1 | 0 | 0 | 0 | 1 | 1 | 5 | 48 | 54 | 55 | 39 | |
| 20 | 46.28 ± 1.08 (44-48) |
0 | 1 | 1 | 0 | 0 | 2 | 0 | 5 | 44 | 49 | 51 | 37 | |
| XPB-L | 40 | 46.61 ± 0.89 (44-48) |
0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 | 34 | 40 | 41 | 29 |
| 60 | 46.53 ± 0.87 (44-48) |
0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 34 | 36 | 36 | 30 | |
| 80 | 46.43 ± 0.96 (44-48) |
0 | 1 | 4 | 0 | 1 | 7 | 1 | 8 | 51 | 60 | 67 | 40 | |
| 100 | 46.42 ± 1.01 (44-48) |
0 | 2 | 4 | 0 | 5 | 11 | 0 | 11 | 77 | 88 | 99 | 45 | |
| 0 | 45.86 ± 0.87 (44-48) |
0 | 0 | 0 | 0 | 0 | 0 | 3 | 21 | 16 | 40 | 40 | 30 | |
| 20 | 45.86 ± 0.87 (44-48) |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 19 | 32 | 32 | 23 | |
| XPD-L | 40 | 45.75 ± 0.86 (44-48) |
0 | 0 | 1 | 0 | 1 | 2 | 0 | 19 | 15 | 34 | 36 | 19 |
| 60 | 45.95 ± 0.86 (44-48) |
2 | 1 | 1 | 0 | 0 | 4 | 6 | 19 | 31 | 56 | 60 | 37 | |
| 80 | 45.90 ± 0.91 (44-48) |
0 | 0 | 1 | 0 | 0 | 1 | 1 | 20 | 34 | 55 | 56 | 31 | |
| 100 | 45.80 ± 1.10 (44-48) |
0 | 1 | 1 | 1 | 0 | 3 | 3 | 10 | 17 | 30 | 33 | 25 | |
T/QLS-Triradial/Quadiradial-like structures; SCF-Sister Chromatid Fusions; D/T-Di/Tricentrics; R-Rings; EAF - End-to-end fusions of acentric fragments; CB-Chromsosome/Chromatid breaks; F-fragments including double minutes, terminal acentric fragments, interstitial acentric fragments and centric fragments; UT-Undetected telomeres. Data is represented as total number of aberrations. A total of 100 spreads were analyzed in two independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, where significance is calculated to the respective cell type's untreated counterpart.